Can a new pill tame rheumatoid arthritis when standard drugs fail?

NCT ID NCT07748728

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing an experimental drug called TLL-018 in adults with moderate-to-severe rheumatoid arthritis who haven't responded well to or couldn't tolerate standard treatments. Participants will receive either TLL-018 or a placebo for a period, and the study will measure how many people experience at least a 20% improvement in joint pain, swelling, and other symptoms. The goal is to see if TLL-018 can safely reduce disease activity and offer a new option for people who need better control of their condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TLL-018, an experimental drug taken as a pill, compared against a placebo
What this could lead to
If successful, TLL-018 could offer a new treatment option for people with rheumatoid arthritis who haven't gotten enough relief from standard medications.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug may not prove effective or safe. It's also possible that any benefits seen here won't hold up in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.